Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 2013 Edition
DUBLIN, April 25, 2013 /PRNewswire/ --
Research and Markets has announced the addition of the "Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 3rd Edition" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:
- In-depth understanding of preclinical stage deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of preclinical stage agreements with numerous real life case studies
- Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies
- Insight into the terms included in a preclinical stage agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech includes
- Trends in preclinical stage dealmaking in the biopharma industry since 2007
- Analysis of preclinical stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life preclinical stage deals
- Access to over 2,200 preclinical stage deals
- The leading preclinical stage deals by value since 2007
- Most active preclinical stage dealmakers since 2007
- The leading preclinical stage partnering resources
In Preclinical Stage Partnering Terms and Agreements in Pharm and Biotech, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Why do companies partner preclinical stage compounds?
Chapter 3 - Preclinical stage deal strategies and structure
Chapter 4 - Preclinical stage partnering payment strategies
Chapter 5 - Trends in preclinical stage deal making
Chapter 6 - Average payment terms for preclinical stage partnering
Chapter 7 - Leading preclinical stage deals
Chapter 8 - Big pharma and big biotech preclinical stage partnering deals
Chapter 9 - Preclinical stage partnering contracts directory
Chapter 10 - Preclinical stage dealmaking directory
For more information visit Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 3rd Edition
Research and Markets
Laura Wood, Senior Manager.
[email protected]
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article